Literature DB >> 32418060

Upregulation of microRNA-532 enhances cardiomyocyte apoptosis in the diabetic heart.

Dhananjie N K Chandrasekera1, Joshua P H Neale1,2, Isabelle van Hout1, Shruti Rawal1,3, Sean Coffey4, Gregory T Jones5, Richard Bunton6, Ramanen Sugunesegran6, Dominic Parry6, Philip Davis6, Patrick Manning4, Michael J A Williams4, Rajesh Katare7.   

Abstract

Type 2 diabetes has a strong association with the development of cardiovascular disease, which is grouped as diabetic heart disease (DHD). DHD is associated with the progressive loss of cardiovascular cells through the alteration of molecular signalling pathways associated with cell death. In this study, we sought to determine whether diabetes induces dysregulation of miR-532 and if this is associated with accentuated apoptosis. RT-PCR analysis showed a significant increase in miR-532 expression in the right atrial appendage tissue of type 2 diabetic patients undergoing coronary artery bypass graft surgery. This was associated with marked downregulation of its anti-apoptotic target protein apoptosis repressor with caspase recruitment domain (ARC) and increased TUNEL positive cardiomyocytes. Further analysis showed a positive correlation between apoptosis and miR-532 levels. Time-course experiments in a mouse model of type 2 diabetes showed that diabetes-induced activation of miR-532 occurs in the later stage of the disease. Importantly, the upregulation of miR-532 preceded the activation of pro-apoptotic caspase-3/7 activity. Finally, inhibition of miR-532 activity in high glucose cultured human cardiomyocytes prevented the downregulation of ARC and attenuated apoptotic cell death. Diabetes induced activation of miR-532 plays a critical role in accelerating cardiomyocytes apoptosis. Therefore, miR-532 may serve as a promising therapeutic agent to overcome the diabetes-induced loss of cardiomyocytes.

Entities:  

Keywords:  Apoptosis; Diabetic heart disease; High glucose; miR-532; microRNA

Mesh:

Substances:

Year:  2020        PMID: 32418060     DOI: 10.1007/s10495-020-01609-1

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  7 in total

1.  Investigating microRNAs in diabetic cardiomyopathy as tools for early detection and therapeutics.

Authors:  Priyanka Mathur; Vibha Rani
Journal:  Mol Cell Biochem       Date:  2022-07-02       Impact factor: 3.396

2.  Downregulation of autophagy-related circular RNA (ACR) is correlated with poor survival of patients with chronic heart failure.

Authors:  Haihui Yan; Dan Du; Chen Wang; Miao Tian
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Diabetes induces dysregulation of microRNAs associated with survival, proliferation and self-renewal in cardiac progenitor cells.

Authors:  Nima Purvis; Sweta Kumari; Dhananjie Chandrasekera; Jayanthi Bellae Papannarao; Sophie Gandhi; Isabelle van Hout; Sean Coffey; Richard Bunton; Ramanen Sugunesegran; Dominic Parry; Philip Davis; Michael J A Williams; Andrew Bahn; Rajesh Katare
Journal:  Diabetologia       Date:  2021-03-02       Impact factor: 10.122

Review 4.  Molecular Mechanisms and Epigenetic Regulation in Diabetic Cardiomyopathy.

Authors:  Anupam Mittal; Rajni Garg; Ajay Bahl; Madhu Khullar
Journal:  Front Cardiovasc Med       Date:  2021-12-16

5.  Increased expression of six-large extracellular vesicle-derived miRNAs signature for nonvalvular atrial fibrillation.

Authors:  Panjaree Siwaponanan; Pontawee Kaewkumdee; Wilasinee Phromawan; Suthipol Udompunturak; Nusara Chomanee; Kamol Udol; Kovit Pattanapanyasat; Rungroj Krittayaphong
Journal:  J Transl Med       Date:  2022-01-03       Impact factor: 5.531

Review 6.  Exosomal microRNAs in diabetic heart disease.

Authors:  Dhananjie Chandrasekera; Rajesh Katare
Journal:  Cardiovasc Diabetol       Date:  2022-07-01       Impact factor: 8.949

7.  CircRNA ACAP2 Is Overexpressed in Myocardial Infarction and Promotes the Maturation of miR-532 to Induce the Apoptosis of Cardiomyocyte.

Authors:  Jun Zhang; Yanrong Tang; Jing Zhang; Jing Wang; Jiyun He; Zhenzhen Zhang; Fuqiang Liu
Journal:  J Cardiovasc Pharmacol       Date:  2021-06-18       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.